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Abstract: Diseases caused by Escherichia coli are recognized as major problems in the swine industry,
one of them being edema disease (ED). Importantly, the current decrease in antibiotic use may cause
difficulties in controlling the disorders caused by E. coli. Therefore, this study assessed the efficacy of
a commercial vaccine against ED in nursery pigs from a farm with previous history of ED. A total of
1344 pigs were monitored; half of them were randomly assigned to a vaccinated group (VG) and the
other half to a non-vaccinated group (NVG). The vaccine was administered at 7 days of age. Animals
received a pre-starter feed with 2500 ppm of zinc oxide (ZnO) for 2 weeks and a starter feed without
ZnO for another 3 weeks. Pen-group weights were recorded at 28 (weaning), 42 (end of pre-starter
phase), and 63 days of life (end of nursery phase). Death/culling rates, average daily gain (ADG),
and average daily feed intake (ADFI) were calculated for each group at each phase. The overall
relative risk of dying/being culled for a pig in the NVG was 5 times higher than that of the VG group
but increased to 12 times higher during the starter period. ADG and ADFI were also significantly
higher in the VG group for that period. Vaccination against ED significantly reduced pig losses and
improved ADG and ADFI, particularly when ZnO was not used.
Keywords: edema disease; vaccination; antibiotic reduction; productive parameters
1. Introduction
Antibiotics have been generally used in swine production to reduce colonization of
pathogenic bacteria in the gut. However, their contribution to the potential development
of antibiotic-resistant strains of bacteria [1] prompted the European Union (EU) to im-
plement a full ban on the use of antibiotics as growth promoters in livestock in January
2006 (Regulation 1831/2003/EC on additives for use in animal nutrition). This measure
was first applied in Sweden and Denmark, leading to an important increase in the preva-
lence of postweaning diarrhea and mortality rates due to Escherichia coli infections [2].
The proliferation of this bacterium can cause a wide range of diseases in pigs, including
postweaning diarrhea (PWD) and edema disease (ED). Postweaning diarrhea is usually
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associated with proliferation of enterotoxigenic E. coli (ETEC) [3]. This pathotype is charac-
terized by the production of enterotoxins and adhesins, both of which essential for disease
development [4]. Edema disease is caused by Shiga-toxin-producing E. coli (STEC), also
known as edema disease E. coli (EDEC). These strains produce the Shiga toxin 2e (Stx2e)
and may possess the fimbriae variants F18ab or F18ac [5].
Antibiotic treatment is still the most widely used therapeutic approach to improve
the health condition of pigs affected with PWD and ED, colistin being one of the main
antimicrobials used before the description of mcr-1 gene, the first reported plasmid gene
encoding resistance to colistin [6]. Additionally, some feed management strategies, such
as restriction of feed intake, reduction of crude protein and digestible energy, high fiber
diets, and ad libitum feeding of fiber, have also been reported as effective in controlling
E. coli infection outbreaks [7]. However, these measures have obvious detrimental effects
on the performance of the animals. Another alternative for controlling E. coli infections has
been the use of in-feed zinc oxide (ZnO), but the European Commission has finally decided
to ban the therapeutic use of ZnO in feed by 2022 due to its contribution to the potential
increase of antimicrobial resistance and environmental issues [8,9].
The Food and Agriculture Organization (FAO) has also emphasized the need to
prevent infectious diseases in animals through several measures compiled into three main
categories: good animal husbandry, effective biosecurity, and vaccination. The latter
induces immune responses that confer protection against the target disease, but some
evidence also suggests that immunization through vaccination may perturb the immune
system in such a way that it might also increase protection against unrelated pathogens [10],
the so called “non-specific effects” (NSE) and, in a wider concept, trained immunity [11].
To date, there are different registered vaccines in Europe for fighting against PWD and
ED. There is a vaccine for reducing mortality and clinical signs due to PWD and early
ED that includes different E. coli bacterins for the passive immunization of piglets [5].
Additionally, a bivalent live vaccine for controlling PWD that comprises F4 and F18 non-
pathogenic E. coli strains does exist [5]. Finally, prevention of EDEC is feasible through
licensed vaccines containing a genetically modified recombinant Stx2e [12].
Considering the permanent need to prevent and control E. coli infections in postwean-
ing pigs and the need to minimize antibiotic usage, the objective of this study was to assess
the global effects (on health and performance) of the use of a licensed vaccine against ED
in a population of nursery piglets from a commercial farm with previous history of ED.
2. Materials and Methods
2.1. Farm Description
The study took place in a commercial 500-sow, farrow-to-nursery herd located in
Segovia (Spain). The farm produced in a 3-week batch farrowing system, following all-in-
all-out procedures. Piglets were weaned at 4 weeks of age and housed in the nursery barn
for 5 weeks. The nursery barn included 7 identical rooms containing 24 pens (8 piglets/pen)
each. Environmental parameters in the nursery barn were set up according to piglet needs.
This farm had clinical history of ED during the starter phase (43–63 days), which
was diagnosed based on clinical signs (nervous signs and sudden death) and laboratory
analyses. STEC infection was identified by detection of genes coding for virulence factors
Stx2e and fimbriae F18 by qPCR (EXOone E. coli virulence factors, Exopol, Spain) from
jejunum content samples from previous ED outbreaks.
When the study was conducted, the farm was positive but stable to porcine re-
productive and respiratory syndrome virus (PRRSV) infection, positive to Mycoplasma
hyopneumoniae, and positive to Porcine circovirus 2 (PCV2) but without evidence of
clinical expression.
Estimated data on the performance of 480 piglets were recorded in the 8 months before
the beginning of this study. These piglets received a commercial feed that included ZnO
(2500 ppm) for the first 14 days and colistin (150 ppm) for 7 days (Table 1).
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Table 1. Performance parameters and incidence rate (I; 1000 piglets-day at risk) of animal losses
during the nursery period in the farm for the period before the beginning of the study, when both
ZnO and colistin were routinely used.
Average Daily Gain (g/d) Average Daily Feed Intake (g/d) I
Pre-starter Starter Pre-starter Starter Pre-starter Starter
171.7 390.7 231.4 554.6 0.149 0.149
Pre-starter: 28–42 days; Starter: 43–63 days.
2.2. Study Design
A total of 1344 nursery pigs from 14 farrowing batches were considered for this study.
At 7 days of age, 8 piglets (4 males and 4 females) from each litter were selected and
ear-tagged after discarding the heaviest and the lightest ones by visual inspection by the
farm veterinarian. Half of the litters were then randomly assigned to a vaccine group
(VG) or a non-vaccine group (NVG) after matching by sow parity. Animals from the VG
were vaccinated against ED (Ecoporc SHIGA®, CEVA, Barcelona, Spain) at that time, while
animals from the NVG were left without vaccine. The dosage applied to piglets was a
single intramuscular injection (1 mL) of a genetically modified recombinant Stx2e antigen
for the active immunization of piglets from the age of 4 days onwards [13]. The onset of
the immunity is 21 days after vaccination, and the duration of immunity 105 days after
vaccination [13].
At weaning, animals were distributed in 168 nursery pens (8 piglets/pen), half with
the VG piglets and the other half with those from the NVG. A commercial pre-starter feed
that included ZnO (2500 ppm) was provided for the first 14 days postweaning and then a
starter feed without ZnO for the last 3 weeks of the nursery period. All the animals were
monitored along the whole nursery period (5 weeks). Since the study was carried out in a
commercial farm, groups could not be blinded, but farm personnel were properly trained
to guarantee that the same monitoring was performed for both groups during the whole
nursery period.
2.3. Data Collection
To measure growth performance parameters, i.e., average daily gain (ADG) and
average daily feed intake (ADFI), piglets were weighed on a pen basis at 28 (weaning),
42 (end of pre-starter feeding), and 63 (end nursery phase) days of life. Feed intake in each
pen was also measured in the same productive phases (days 28–42 and 43–63).
Both culled and dead piglets were recorded throughout the nursery period. Date of
death/culling, weight, and possible cause of death/culling were also registered. Data of
dead/culled piglets were considered for growth performance parameter estimates within
the corresponding phase.
2.4. Statistical Analyses
The frequency at which piglets died or were culled from the population over the
period of nursery, that is, the incidence rate per 1000 piglets-day at risk (I), was estimated
as [14]:
I =
number of dead/culled piglets occurring in a period of time × 1000
sum of times (in days) at risk of dying/being culled of all piglets
I was calculated for each group and for each phase of the nursery period (pre-starter
and starter). The relative risk (RR), i.e., the ratio of the I in the NVG (INVG) to the I in
the VG (IVG), and their corresponding 95% confidence intervals (95%CI) were further
estimated for the pre-starter and the starter phases.
The pen was used as the experimental unit for comparison of growth performance
data (ADG, ADFI) between groups. For this purpose, analysis of variance using the GLM
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procedure of SAS was used, and group differences were tested using Tukey’s test [15].
Statistical significance was set at p < 0.05 for all analyses.
3. Results
A total of 30 piglets out of the 1344 included in the study died or were culled during
the nursery period. For 25 of them, death occurred during the starter period (43–63 days of
age). A description of the number of piglets dead or culled and the clinical signs observed
are presented in Table 2. Overall, diarrhea (n = 10) was the most frequent cause of piglet
death/culling, followed by wasting (n = 9).





VG NVG VG NVG Total (Percentage)
Diarrhea 1 2 1 6 10 (33.3%)
Runts 1 1 7 9 (30.0%)
Respiratory problems 5 5 (16.7%)
Nervous signs 2 2 (6.7%)
Lameness 1 1 (3.3%)
Sudden death 1 1 (3.3%)
Accident 1 1 (3.3%)
Unknown 1 1 (3.3%)
Subtotals 3 2 2 23
Total 5 25 30 (100%)
Pre-starter: 28–42 days; Starter: 43–63 days. VG (vaccinated group against ED); NVG (non-vaccinated group).
The I of death/culled piglets, although low, was significantly higher for the NVG
compared with the VG (1.1 vs. 0.21 1000 piglets-day at risk; p < 0.001) during the nursery
period. Thus, the RR of dying/being culled for a pig in the NVG was around 5 times
higher than that of the VG group (5.04; 95%CI: 3.89–6.54). This risk was negligible for the
pre-starter period (28–42 days of life) but increased to almost 12 times when only the starter
period (43–63 days) was considered (Table 3). This difference between the pre-starter and
the starter periods remained significant even when comparing deaths and runts separately
(data not shown).
Table 3. Estimates of incidence rate (I; 1000 piglets-day at risk) for the non-vaccinated (NVG) and
vaccinated (VG) groups for each period of nursery (pre-starter and starter) and corresponding relative
risk (RR) between them.
Group Pre-Starter (28–42 Days of Life) Starter (43–63 Days of Life)
D R TL I RR (95%CI) p D R TL I RR (95%CI) p
NVG 2 0 2 0.21
0.66 (0.4–1.2) 0.84
16 7 23 1.6
11.7 (2.7–49.5) <0.001
VG 2 1 3 0.32 1 1 2 0.14
VG (vaccinated group against ED); NVG (non-vaccinated group). p (p-value) < 0.05 is indicative of significant
differences for a given period. D (No. deaths); R (No. runts); TL (No. of total losses).
Body weight at the beginning of the study was not significantly different between the
VG and the NVG group (7.65 vs. 7.54 kg, respectively; p = 0.26). ADG and ADFI for the
pre-starter and starter periods are presented for the VG and NVG in Table 4. The ADG and
ADFI of the starter period were significantly higher in the VG group compared with those
of the NVG.
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Table 4. Average daily weight gain and average daily feed intake results for the different
studied groups.









VG 171.4 387.3 227.3 563.6
NVG 176.6 375.0 230.5 541.4
p 0.287 0.040 0.472 0.010
VG (vaccinated group against ED); NVG (non-vaccinated group). p (p-value) < 0.05 is indicative of significant
differences for a given period.
4. Discussion
Edema disease caused by Stx2e-producing strains of E. coli can be a significant eco-
nomic disorder in a pig production farm [12]. The cost of associated outbreaks depends on
the mortality rate and weight of the pigs that die (the older the pigs, the more expensive
the consequences). In addition to these direct losses, a possible immunosuppressive effect
of the Stx2e toxin is also suspected [16], which may affect whether piglets thrive properly.
Vaccination is considered one of the main alternatives for protecting the piglets against
this disease, avoiding the use of antimicrobials that may trigger the selection for antimi-
crobial resistance [17]. In this study, a vaccine against Stx2e was used in a farm where
STEC was previously confirmed, and vaccinated and non-vaccinated pigs were monitored
along the whole nursery period. A significantly lower (5 times less) number of losses
(dead or culled pigs) were observed among the vaccinated piglets compared with those in
non-vaccinated group during the nursery period.
Some of the losses within the NVG were associated with clinical signs that could
be related to ED, such as neurological disorders, sudden death, wasting (runts), and
diarrhea [5], but no laboratory analyses were specifically performed to confirm the etiologic
agent of the clinical signs. Thus, it is likely that some of them may be attributed to other
infectious agents potentially present in the farm (i.e., Glaesserella parasuis, Streptococcus
suis, or Pasteurella multocida). It cannot be ruled out that part of the positive vaccination
results might be attributed to NSE or trained immunity, since specific immunity is initiated
by non-specific innate immune mechanisms [10,11]. In addition, aluminum hydroxide-
based adjuvants, the type of adjuvant in the tested vaccine, may also contributed to the
stimulation of these innate immune responses [18].
One of the most common clinical scenarios of ED is associated with losses occurring
from 2 to 4 weeks postweaning, after the change of feed from pre-starter to starter [19].
Other factors that have been associated with increase of ED incidence are the withdrawal
of ZnO or of antibiotics from feed, along with any stressor agent, such as transportation,
mixing of pigs, presence of other infections, etc. [5]. In the present study, both the NVG
and the VG experienced a change in feed (pre-starter to starter) and the withdrawal of
the in-feed administration of ZnO at the same time, which was routinely used for two
weeks after weaning to limit proliferation of enteropathogenic E. coli [20]. However, this
pattern of losses was only observed in the NVG, not in the VG. The incidence rate of
mortality/culling was significantly higher during the starter period for the NVG, which
suffered from almost 12 times higher risk of losses (RR = 11.7; 95%CI: 2.7–49.5) compared
with the VG. Thus, it appears that vaccination against Stx2e may have prevented further
losses in the VG during the starter phase of the nursery period.
Although a direct comparison between mortality (deaths plus runts) in this VG and
mortality in a previous period, in which a combination of colistin and ZnO was used, could
not be properly conducted because the groups may differ, it is interesting to highlight that
mortality was virtually the same during the starter phase for both groups (0.14 vs. 0.15
1000 piglets-day at risk, respectively). The vaccine used in the present study, based on a
genetically modified recombinant Stx2e, has already been shown to be apparently effective
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in reducing the use of colistin and the mortality rate (MR) during the nursery period [12,21].
Thus, this study supports previous results suggesting that vaccination against Stx2e may
reduce mortality and may likely be used as an alternative to the use of colistin.
Effects of vaccination were noted on performance parameters as well. During the
starter period, the ADG in the VG was significantly better than that in the NVG (387.3 g/d
vs. 375 g/d, p = 0.04). Better ADG results for the vaccinated groups were also found in
the nursery period in the abovementioned German study of Lillie-Jaschniski et al. (2013).
These results are of great importance, as ADG during the nursery period has a major impact
on subsequent growth performance [22].
Interestingly, ED occurs mostly in the best pigs, those that also show higher feed
intake, which would favor the imbalance of microbiota and the proliferation of pathogenic
E. coli [23,24]. In this study, during the starter period, the ADFI for the VG was significantly
larger than that in the NVG (563.6 g/d vs. 541.4 g/d, p = 0.010). It appears that despite
this higher feed consumption in the VG, along with other risk factors present such as the
withdrawal of ZnO and the feed change, the vaccine would have helped to keep mortality
significantly lower compared with the NVG.
5. Conclusions
Considering that the metaphylactic use of antibiotics is not advisable and that ZnO will
be banned by 2022, alternatives for controlling the effects of ED during the nursery period
should be explored. The present study showed that after vaccination against Stx2e in a farm
with previous history of ED, postweaning losses were reduced during the whole nursery
period, and performance parameters improved in the starter period, thus suggesting that
this approach could be a useful alternative to colistin and/or ZnO.
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